The safety and efficacy of immunotherapy with anti-programmed cell death 1 monoclonal antibody for lung cancer complicated with Mycobacterium tuberculosis infection

BACKGROUND: Anti-programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immunotherapy has boosted the prognosis in advanced lung cancer. Meanwhile, accumulating cases showed the correlation between tuberculosis (TB) reactivation and anti-PD-1/PD-L1 immunotherapy. However, the safety a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jinpeng, Li, Jiayu, Wang, Qi, Cheng, Xiaomin, Du, He, Han, Ruoshuang, Li, Xuefei, Zhao, Chao, Gao, Guanghui, He, Yayi, Chen, Xiaoxia, Su, Chunxia, Ren, Shengxiang, Wu, Fengying, Zhang, Zhemin, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577979/
https://www.ncbi.nlm.nih.gov/pubmed/34858782
http://dx.doi.org/10.21037/tlcr-21-524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577979/
https://www.ncbi.nlm.nih.gov/pubmed/34858782
http://dx.doi.org/10.21037/tlcr-21-524

Ejemplares similares